Your browser is no longer supported. Please, upgrade your browser.
Settings
SNGX Soligenix, Inc. daily Stock Chart
SNGX [NASD]
Soligenix, Inc.
Index- P/E- EPS (ttm)-0.91 Insider Own- Shs Outstand6.08M Perf Week29.43%
Market Cap16.29M Forward P/E- EPS next Y-0.68 Insider Trans- Shs Float4.97M Perf Month24.62%
Income-3.80M PEG- EPS next Q-0.28 Inst Own6.90% Short Float6.62% Perf Quarter-35.44%
Sales9.10M P/S1.79 EPS this Y69.00% Inst Trans-20.32% Short Ratio1.23 Perf Half Y8.04%
Book/sh1.06 P/B2.53 EPS next Y42.40% ROA-48.10% Target Price7.33 Perf Year-58.78%
Cash/sh1.17 P/C2.29 EPS next 5Y1.00% ROE-99.30% 52W Range1.90 - 8.50 Perf YTD19.08%
Dividend- P/FCF- EPS past 5Y15.60% ROI-64.70% 52W High-68.48% Beta2.40
Dividend %- Quick Ratio3.20 Sales past 5Y6.40% Gross Margin20.30% 52W Low41.02% ATR0.23
Employees19 Current Ratio3.20 Sales Q/Q-50.00% Oper. Margin-55.70% RSI (14)61.72 Volatility18.71% 7.70%
OptionableNo Debt/Eq0.00 EPS Q/Q13.80% Profit Margin-41.90% Rel Volume1.13 Prev Close2.87
ShortableYes LT Debt/Eq0.00 EarningsAug 10 Payout- Avg Volume267.21K Price2.68
Recom2.00 SMA2022.60% SMA5017.16% SMA200-9.08% Volume303,064 Change-6.64%
Jul-17-17Initiated H.C. Wainwright Buy $11
Jul-18-17 08:10AM  Today's Research Reports on Stocks to Watch: Soligenix and Aurinia Pharmaceuticals Accesswire -11.76%
Jul-06-17 06:00AM  Dusquetide Technology Platform to be Presented at the 2017 Drug Discovery and Therapy World Congress PR Newswire
Jun-21-17 06:00AM  Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine PR Newswire
Jun-19-17 06:00AM  Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference PR Newswire +8.91%
Jun-13-17 10:02AM  Soligenix, Inc. :SNGX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017 Capital Cube
Jun-07-17 09:00AM  What Biotech Offers a Better Risk/Reward Profile than Soligenix (SNGX)? In Our View, None Accesswire
May-18-17 06:00AM  Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients PR Newswire
May-11-17 11:00AM  SNGX: SGX942: Cancer Control is an Added Bonus for OM Treatment Zacks Small Cap Research
06:00AM  Soligenix Announces Recent Accomplishments And First Quarter 2017 Financial Results PR Newswire
May-10-17 02:54PM  With Two Phase III Trials Operational & Significant Financial Leverage, Soligenix Shining Accesswire
May-09-17 06:00AM  Soligenix Receives Japanese Patent for ThermoVax® Vaccine Heat Stabilization Platform Technology PR Newswire
May-03-17 06:00AM  Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients PR Newswire
Apr-20-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Soligenix and MannKind Accesswire
Apr-19-17 06:30AM  Efficacy Results from Soligenix's Ricin Toxin Vaccine Program to be Presented at the 20th Annual Conference on Vaccine Research PR Newswire +43.58%
Apr-12-17 06:00AM  Soligenix to Present at the World Orphan Drug Congress PR Newswire +9.24%
Apr-04-17 09:00AM  Statistically Significant Data from Late Stage Clinical Assets & Continued Funding from the Government Positions Soligenix Attractively for a Potential Suitor Accesswire
09:00AM  Statistically Significant Data from Late Stage Clinical Assets & Continued Funding from the Government Positions Soligenix Attractively for a Potential Suitor
Mar-31-17 01:04PM  SOLIGENIX, INC. Financials
Mar-29-17 09:39AM  Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017 Capital Cube +8.21%
09:39AM  Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
Mar-27-17 05:19PM  SOLIGENIX, INC. Files SEC form 10-K, Annual Report
07:30AM  Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results PR Newswire
Mar-15-17 06:30AM  Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 19th Annual Superbugs & Superdrugs Conference PR Newswire
Mar-13-17 01:00PM  Soligenix (SNGX): A Key Player in the Biodefense Space Zacks Small Cap Research +12.64%
01:00PM  Soligenix (SNGX): A Key Player in the Biodefense Space
Mar-10-17 06:30AM  Soligenix to Present Results from its Ricin Toxin Vaccine Program at the Society of Toxicology 56th Annual Meeting PR Newswire +12.02%
Feb-23-17 04:58PM  SOLIGENIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -10.08%
Feb-22-17 10:00AM  SNGX: Potential Expansion of Synthetic Hypericin into Psoriasis Zacks Small Cap Research +8.18%
10:00AM  SNGX: Potential Expansion of Synthetic Hypericin into Psoriasis
06:00AM  Soligenix Receives European Patent for Formulation of Synthetic Hypericin to Treat Psoriasis PR Newswire
Feb-02-17 06:00AM  Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency PR Newswire
Jan-18-17 04:27PM  SOLIGENIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -8.73%
Jan-06-17 06:00AM  Soligenix to Present at 9th Annual Biotech Showcase Conference PR Newswire
Jan-05-17 11:00AM  Soligenix (SNGX): SGX942 (Dusquetide) Could be A Game Changer for the Treatment of Oral Mucositis +5.49%
06:00AM  Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients PR Newswire
Jan-03-17 07:00AM  Soligenix Announces Extension of Development Agreement with Emergent BioSolutions PR Newswire +5.33%
Dec-20-16 07:00AM  Soligenix Advances Collaboration with IDT Biologika PR Newswire
Dec-16-16 05:03PM  SOLIGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements an
04:23PM  Soligenix Announces Closing of Public Offering PR Newswire
Dec-13-16 02:00PM  Soligenix (SNGX) Prices $5.3 million Public Offering and Completes Listing on Nasdaq -34.01%
06:05AM  Soligenix, Inc. Prices $5,277,000 Public Offering and Completes Listing on Nasdaq PR Newswire
Dec-12-16 07:00AM  Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency PR Newswire +11.58%
Dec-09-16 10:00AM  SNGX: Positive Long-Term Results Reported from Phase II SGX942 for the Treatment of Oral Mucositis
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.